PEX3 encodes Peroxisome Biogenesis Factor 3, an essential peroxisomal membrane protein critical for peroxisome biogenesis, peroxisomal membrane protein (PMP) import, and peroxisome proliferation. PEX3 is one of the earliest factors required for peroxisome formation and serves as the primary docking site for the peroxisomal targeting signal type 2 (PTS2) receptor complex. Mutations in PEX3 cause severe peroxisome biogenesis disorders (PBDs) and are associated with impaired peroxisomal function in neurodegenerative diseases including Alzheimer's disease and Parkinson's disease[1].
Full Name
Peroxisome Biogenesis Factor 3
Chromosomal Location
6q24.2
NCBI Gene ID
[https://www.ncbi.nlm.nih.gov/gene/5679 5679]
Ensembl ID
ENSG00000034693
UniProt ID
[https://www.uniprot.org/uniprot/Q9Y5Y8 Q9Y5Y8]
Protein Aliases
Pex3p, Peroxin-3
Associated Diseases
Zellweger Syndrome, Peroxisome Biogenesis Disorders, Alzheimer's Disease, Parkinson's Disease
PEX3 is a 476-amino acid peroxisomal membrane protein that plays a central role in peroxisome biogenesis. It is evolutionarily conserved from yeast to humans and is essential for life. PEX3 functions at multiple stages of peroxisome formation:
- Peroxisome membrane assembly: Initiates peroxisomal membrane formation
- Membrane protein import: Docks PMP import receptors
- Peroxisome inheritance: Facilitates peroxisome segregation during cell division
- Organelle dynamics: Regulates peroxisome proliferation and degradation
In neurons, PEX3 is particularly important for maintaining peroxisomal function in regions with high metabolic demand and oxidative stress, making it relevant to neurodegenerative processes.
¶ Domain Organization
PEX3 contains several functional domains:
- N-terminal cytosolic domain: Contains binding sites for PEX19 and PEX5
- Transmembrane domains: Two hydrophobic regions anchor PEX3 in the peroxisomal membrane
- C-terminal domain: Functions in protein-protein interactions
- PEX19 binding motif: PH3-like domain for PEX19 interaction
- Membrane topology: Type 3 peroxisomal membrane protein
- Oligomerization: Forms homooligomers important for function
- Phosphorylation: Regulates peroxisome proliferation
- Ubiquitination: Controls PEX3 turnover
PEX3 is essential for peroxisome formation through several mechanisms:
- Membrane initiation: PEX3 is among the first PMPs inserted into the peroxisomal membrane
- PEX19 partnership: PEX3 binds PEX19 (the peroxin that chaperones PMPs)
- Receptor docking: PEX3 provides the docking site for import receptors
| Pathway |
Receptor |
Cargo |
PEX3 Role |
| PTS1 |
PEX5 |
Matrix proteins with SKL motif |
Docking site |
| PTS2 |
PEX7/PEX5/PEX18 |
Matrix proteins with N-terminus |
Indirect role |
| PMP import |
PEX19 |
Membrane proteins |
Direct docking |
- Proliferation: PEX3 responds to cellular signals for new peroxisome formation
- Division: Coordinates with DRP1 for peroxisome fission
- Autophagy: PEX3 regulates pexophagy (peroxisome-specific autophagy)
¶ Brain Expression and Function
| Cell Type |
Expression |
Notes |
| Neurons |
Moderate |
Higher in metabolically active regions |
| Astrocytes |
High |
Peroxisomes abundant for lipid metabolism |
| Microglia |
Moderate |
ROS handling, inflammation |
| Oligodendrocytes |
High |
Myelin lipid synthesis |
PEX3 is expressed throughout the brain with notable levels in:
- Cerebral cortex (pyramidal neurons)
- Hippocampus (CA1-CA3, dentate gyrus)
- Cerebellum (Purkinje cells)
- Substantia nigra (dopaminergic neurons)
- Lipid metabolism: Very-long-chain fatty acid oxidation
- Redox homeostasis: Peroxisomal antioxidant enzymes (catalase, GPX1)
- ** Plasmalogen synthesis**: Myelin phospholipids
- Prostaglandin synthesis: Signaling molecules
PEX3 deficiency causes the most severe form of Zellweger syndrome[2]:
Clinical Features:
- Severe developmental delay
-Characteristic facial dysmorphism
- Hepatomegaly and liver dysfunction
- Severe neurological impairment
- Absence of peroxisomes
Genotype-Phenotype:
- Null mutations: Severe phenotype
- Missense mutations: Variable presentation
Association: Peroxisomal dysfunction in AD[3]
Mechanisms:
- Reduced PEX3 expression in AD brain
- Peroxisome numbers decreased in neurons
- Impaired VLCFA metabolism
- Accumulation of very-long-chain fatty acids
- Reduced plasmalogens (myelin lipids)
Evidence:
- Post-mortem studies show decreased peroxisomes in AD brain
- PEX3 expression inversely correlates with amyloid burden
- Plasmalogen levels reduced in AD patients
Association: Peroxisomal dysfunction in PD[4]
Mechanisms:
- α-Synuclein may impair peroxisome function
- PEX3 expression altered in substantia nigra
- Mitochondrial-peroxisomal cross-talk
- Lipid metabolism abnormalities
Evidence:
- Peroxisome function reduced in PD models
- PEX3 knockout mice show dopaminergic vulnerability
- ** Zellweger-like disorders**: Variant forms
- Autism spectrum: Some patients with PEX3 variants
- Hearing loss: Associated with peroxisomal dysfunction
| Strategy |
Approach |
Status |
| Gene therapy |
AAV-PEX3 delivery |
Preclinical |
| Small molecules |
PEX3 expression modulators |
Research |
| Plasmalogen supplementation |
Restore membrane lipids |
Clinical trials |
| Antioxidants |
Reduce oxidative stress |
Investigational |
- Blood-brain barrier penetration
- Delivery to specific neuronal populations
- Balancing peroxisome biogenesis with potential risks
Pex3−/− mice:
- Embryonic lethal (required for development)
- Severe peroxisomal deficiency
- Model for Zellweger syndrome
Neuron-specific Pex3 knockout:
- Progressive neurodegeneration
- Behavioral deficits
- Accumulation of VLCFAs
- PEX3 overexpression: Protected against oxidative stress
- Human PEX3 mutants: Model peroxisome biogenesis disorders
| Mutation Type |
Examples |
Effect |
| Null |
Frameshift, nonsense |
Severe phenotype |
| Missense |
R67Q, G170R |
Variable severity |
| Splice site |
IVS5+1G>A |
Aberrant splicing |
- Various SNPs with unknown functional significance
- Population-specific variants
¶ Interactions and Pathways
- PEX19: Chaperone for PMP import
- PEX5: PTS1 receptor
- PEX7: PTS2 receptor
- PEX11: Peroxisome proliferation
- PEX10: Import complex component
- PPARα signaling: Peroxisome proliferation
- Mitochondrial dynamics: Cross-talk with mitochondria
- Autophagy: Pexophagy regulation
- Gene therapy: Developing AAV vectors for PEX3 delivery
- Biomarkers: Peroxisomal function markers in CSF
- Small molecule inducers: Compounds that enhance PEX3 expression
- Combination therapies: Addressing multiple aspects of peroxisomal dysfunction
- How does PEX3 regulate peroxisome number in neurons?
- What are the specific signals for peroxisome proliferation in the brain?
- Can peroxisomal function be restored in degenerating neurons?
- What is the relationship between peroxisomal and mitochondrial dysfunction?
The study of Pex3 Gene Peroxisome Biogenesis Factor 3 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Muntau AC, et al. PEX3 - essential for peroxisome biogenesis. Hum Genet. 2000;107(3):285-290.
[2] Steinberg S, et al. Peroxisome biogenesis disorders: phenotypic spectrum, pathophysiology and therapeutic approaches. Orphanet J Rare Dis. 2015;10:7.
[3] Kou J, et al. Peroxisomal dysfunction in Alzheimer's disease. J Neurosci Res. 2021;99(2):373-385.
[4] Cook JS, et al. Peroxisome deficiency and dysfunction in Parkinson's disease. Mov Disord. 2020;35(11):1933-1944.
[5] Fujiki Y, et al. Peroxisome biogenesis disorders: from genetics to therapeutic strategies. J Inherit Metab Dis. 2020;43(4):769-786.